Targeted Therapeutics, Multiple Modalities Driving the $20 Billion U.S. Cancer Therapeutics Market, According to Report from MedMarket Diligence

New report issued by MedMarket Diligence on products, technologies and markets for cancer therapeutics. The report provides detailed incidence and prevalence data, trends in clinical practice and the competitors market shares and market outlook for a range of products in cancer therapeutics

(PRWEB) October 27, 2003 --Personalized therapeutics that match intervention to the typc, location, morphology and other tumor-specific and patient-specific criteria characterize two-thirds of the roughly 400 cancer medicines in development, according to a new report from MedMarket Diligence. Immunotherapies, antisense therapies and gene therapies have advanced to trials and are revealing exciting benefits as standalone or adjunctive therapeutics.

While the vast bulk of the market for cancer therapeutics continues to be in pharmaceuticals, the level of activity and sophistication in the development of biotherapeutics is evidence of the promise in what most of these provide, and thats their precision as targeted therapeutics," says Patrick Driscoll, President of MedMarket Diligence. This heightened ability to more precisely destroy or arrest each tumor without causing collateral tissue damage, according to Driscoll, is reason why these technologies will see market growth in excess of 30% annually within the next few years.

Advances in cancer treatment are not limited to developments in biotherapeutics. Technologies that have already had an impact on the market will demonstrate equally strong growth. These include micro-delivery systems, energy-based tissue ablation systems, brachytherapy and others. Another significant trend in cancer therapy is the use of multiple modalities to further enhance the specificity of each treatment.

The MedMarket Diligence report analyzes the current and emerging products, technologies and markets involved in oncology encompassing detection & diagnostic systems, drug delivery devices, chemotherapy, ablation, orthotics & prosthetics, radiation therapy, biological therapies, pharmaceuticals, transplantation and emerging technologies. The report provides a forecast to 2013 of the U.S. markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report also profiles over 80 key companies in this industry, detailing their current products, current market position and products under development. More details can be found at http://www.mediligence.com/rpt-d101.htm.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. In addition to medical technology reports, MedMarket Diligence publishes MedMarkets, which analyzes the market implications of new medical technology. For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail info@mediligence.com, or visit the website at http://www.mediligence.com to view a sample issue of MedMarkets and see a list other published and forthcoming reports.
###